Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06288802
Other study ID # 04-2023-200647
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 15, 2020
Est. completion date December 2024

Study information

Verified date February 2024
Source South Egypt Cancer Institute
Contact Mahmoud Elzembely, MD
Phone +201146703107
Email elzimbily@aun.edu.eg
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this cross sectional observational study is to determine the percentage of Wilms tumors among pediatric cancers at Shefa Al-Orman Children Cancer Hospital from june 2020 to june 2024,to study the outcome of patients with Wilms tumor treated according to SIOP Umbrella protocol during the study period and to study the treatment related complications during therapy according to common terminology criteria of adverse events version 5.0 (CTCAE Version 5.0).


Description:

Research Design and Methods: Study design: cross sectional study Study setting: Shefa Al-Orman Children Cancer hospital Study period: from June 2020 to June 2024 Study Objectives: 1. To determine the percentage of Wilms tumors among pediatric cancers. 2. To study the outcome of patients with Wilms tumor treated according to SIOP Umbrella protocol (1). 3. To study the treatment related complications during therapy according to common terminology criteria of adverse events version 5.0 (CTCAE Version 5.0) (2). Data collection: Each patient is subjected to all the following according to the centre policy: I. History and physical examination at presentation: 1. Demographic data as: Age, sex, residence and date of diagnosis. 2. Clinical history and Physical examination including - Initial signs and symptoms of pediatric renal tumors including palpable abdominal mass, abdominal pain, hypertension, hematuria, weight loss, constipation, diarrhea, urinary tract infection, previous trauma….etc. - Associated congenital anomalies including. Aniridia, genitourinary anomalies, hemihypertrophy - Family history of cancer II. Laboratory studies done for diagnosis of renal tumors at presentation: - Complete blood count: presence/absence of polycythemia, anemia, thrombocytopenia - Serum chemistries: blood urea nitrogen, creatinine, uric acid, Alanin transaminases, aspartate aminotransferase, serum bilirubin. - Assessment of coagulation factors: prothrombin time, partial thromboplastin time III. Imaging Studies: 1. Abdominal ultrasound 2. Abdominal CT scan or MRI with special attention to * Presence and function of the opposite kidney *Evidence of bilateral lesions *Evidence of involvement of renal vein or inferior vena cava with tumor *Lymph node involvement *Liver metastasis 3. Chest computed tomography scan. 4. Echocardiography: To - Assess myocardial contractility before starting cardiotoxic chemotherapy. - Detect the presence of tumor in the inferior vena cava or right atrium IV. Pathology: 1. Ultrasound or CT guided True cut needle biopsy is indicated in the following conditions: A- Unusual clinical presentations: - Age > 5-6 years or less than 6 months B- Unusual findings by imaging: - Calcification - Voluminous adenopathies - Renal parenchyma not visible - Almost totally extrarenal process C- Contraindications for the use of Needle Biopsy: - Suspicion of rupture or hemorrhage - Needle biopsy is unlikely to be of benefit in pure cystic structures with no solid component. Immediate surgery to establish the diagnosis is recommended in such cases. V. Reporting of treament related complications include: Chemotherapy toxicity will be determined according to WHO Common Terminology Criteria for Adverse Events (CTCAE Version 5.0, 2017) (2). VI. Treatment: Patients are treated according to SIOP Umbrella protocol (1)


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date December 2024
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group N/A to 18 Years
Eligibility Inclusion Criteria: - Children and young adolescene younger than 18 years of age admitted and treated at Shefa Al-orman Children Cancer Hospital during the study period Exclusion Criteria: - Patients aged older than 18 years old, died early at presentation before starting chemotherapy, patients with non-Wilms renal tumors, relapsed renal tumors.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Egypt Shefa Al-orman Children Cancer Hospital Luxor

Sponsors (3)

Lead Sponsor Collaborator
South Egypt Cancer Institute Assiut University, Shefa Al-orman Children Cancer Hospital

Country where clinical trial is conducted

Egypt, 

References & Publications (2)

Basch E, Becker C, Rogak LJ, Schrag D, Reeve BB, Spears P, Smith ML, Gounder MM, Mahoney MR, Schwartz GK, Bennett AV, Mendoza TR, Cleeland CS, Sloan JA, Bruner DW, Schwab G, Atkinson TM, Thanarajasingam G, Bertagnolli MM, Dueck AC. Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Clin Trials. 2021 Feb;18(1):104-114. doi: 10.1177/1740774520975120. Epub 2020 Dec 1. — View Citation

van den Heuvel-Eibrink MM, Hol JA, Pritchard-Jones K, van Tinteren H, Furtwangler R, Verschuur AC, Vujanic GM, Leuschner I, Brok J, Rube C, Smets AM, Janssens GO, Godzinski J, Ramirez-Villar GL, de Camargo B, Segers H, Collini P, Gessler M, Bergeron C, Sp — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Overall-survival (OS) will be calculated from date of diagnosis to last date of follow up or date of death for any cause from date of diagnosis to last date of follow up or date of death for any cause
Secondary Event-free survival (EFS) will be measured from the date of Wilms tumor diagnosis to the first treatment failure or date of last follow-up. Treatment failure included abandonment of treatment, death, and progressive or relapsed disease. the date of Wilms tumor diagnosis to the first treatment failure or date of last follow-up. Treatment failure included abandonment of treatment, death, and progressive or relapsed disease.
See also
  Status Clinical Trial Phase
Completed NCT01222780 - To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer Phase 1
Completed NCT03655587 - Impact of an Orthotic Intervention in Children With Peripheral Neuropathy N/A
Recruiting NCT05384821 - Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906) Phase 1/Phase 2
Active, not recruiting NCT03233204 - Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Phase 2
Completed NCT01661400 - Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors Phase 1
Terminated NCT02536183 - A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors Phase 1
Completed NCT01252901 - Registry for Patients With Wilms' Tumor Suppressor Gene 1 (WT1) Mutation Associated Diseases N/A
Completed NCT02452554 - Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma Phase 2
Recruiting NCT04851119 - Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Phase 1/Phase 2
Active, not recruiting NCT03220035 - Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Active, not recruiting NCT03213678 - Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Completed NCT00187031 - A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor Phase 2
Completed NCT04956198 - Drug Sensitivity and Mutation Profiling
Active, not recruiting NCT03698994 - Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Active, not recruiting NCT03213665 - Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Recruiting NCT04791228 - A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors Phase 2
Active, not recruiting NCT04320888 - Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Phase 2
Completed NCT02714790 - Prognostic Role of Minimal Residual Disease in Acute Myeloid Leukemia N/A
Completed NCT01095926 - Pharmacokinetic Study of Doxorubicin in Children With Cancer Phase 2
Active, not recruiting NCT02867592 - Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Phase 2